what companies make glp 1 drugs Comparing Ozempic, Wegovy and Other GLP-1 Novo Nordisk was the first
Description
However, prescriber criteria does not list prediabetes as an eligible comorbidity under 30+ bmi
Heart Failure Current evidence overall does not support the routine use of GLP-1 RAs to improve cardiac function or reduce HF hospitalizations
1991;261(2 Pt 2):R501-507
doi: 10.1016/S0140-6736(21)01324-6 71 FrasJPDaviesMJRosenstockJPrez ManghiFCFernndez LandLBergmanBKet al
Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025
[DOI] [PubMed] [Google Scholar] 149.Vrs I., Ondi Z., Tth V.., Gergely T.G., Sghy ., Grbe A., Kemny ., Leszek P., Helyes Z., Ferdinandy P., et al
